Prof. Matthias Tschöp

Prof. Matthias Tschöp, Helmholtz Zentrum München/Deutsches Forschungszentrum für Gesundheit und Umwelt, Neuherberg, Germany

Matthias Tschöp is the CEO of Helmholtz Munich, VP of the Helmholtz Association and AvH Professor at the Technical University of Munich. He unraveled fundamental gut-brain signals to discover the first highly effective drugs for human obesity in collaboration with the chemist Richard DiMarchi – the dual and triple gut hormone multi-agonists. A first representative is FDA-approved. Tschöp has received numerous awards, including the Banting Medal, the Heinrich Wieland Prize and the Ernst Schering Prize. He holds an adjunct professorship at Yale University, honorary doctorate sat Leipzig University and Stockholm University. He was elected a member of the German, Bavarian, and European Academies of Sciences, the American Society for Clinical Investigation and the Association of American Physicians.